PMID- 35782324
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2221-285X (Electronic)
IS  - 1818-0876 (Print)
IS  - 1818-0876 (Linking)
VI  - 17
IP  - 3
DP  - 2022 May
TI  - Changes in target ability of nanoparticles due to protein corona composition and 
      disease state.
PG  - 401-411
LID - 10.1016/j.ajps.2022.03.002 [doi]
AB  - Many studies have shown the influence of protein corona (PC) on the active 
      targeting capability of ligand-modified nanoparticles; however, the influence of 
      clinical status on PC composition and targeting capacity is rarely discussed. In 
      this study, when transferrin-modified PEGylated polystyrene nanoparticles 
      (Tf-PNs) is intravenously injected into mice with non-small cell lung cancer 
      (NSCLC) comorbid with type 2 diabetes mellitus (T2DM), more Tf-PNs accumulated in 
      the tumor tissue than in those of NSCLC model mice. This indicated that PC 
      derived from different states of disease changed the active targeting ability of 
      Tf-PNs. To explain the occurrence of this phenomenon, our analysis of PC from 
      different disease states revealed that Tf (transferrin) modification had no 
      significant effect on the formation of PC, and that the PC from the NSCLC 
      comorbid with T2DM model contained more proteins like fibrin and clusterin. This 
      work demonstrates the impacts of comorbidity, such as with T2DM, on the active 
      targeting capability of ligand-modified nanoparticles, and the results promote 
      the application of nanoparticles for precision medicine.
CI  - (c) 2022 Shenyang Pharmaceutical University. Published by Elsevier B.V.
FAU - Xu, Wenwen
AU  - Xu W
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan 
      Research Center for Drug Precision Industrial Technology, West China School of 
      Pharmacy, Sichuan University, Chengdu 610064, China.
FAU - Xu, Mingyu
AU  - Xu M
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan 
      Research Center for Drug Precision Industrial Technology, West China School of 
      Pharmacy, Sichuan University, Chengdu 610064, China.
FAU - Xiao, Yumeng
AU  - Xiao Y
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan 
      Research Center for Drug Precision Industrial Technology, West China School of 
      Pharmacy, Sichuan University, Chengdu 610064, China.
FAU - Yu, Lu
AU  - Yu L
AD  - Chengdu Finelyse Pharmaceutical Technology Co. ltd, Chengdu 610064, China.
FAU - Xie, Huiru
AU  - Xie H
AD  - Chengdu Finelyse Pharmaceutical Technology Co. ltd, Chengdu 610064, China.
FAU - Jiang, Xuehua
AU  - Jiang X
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan 
      Research Center for Drug Precision Industrial Technology, West China School of 
      Pharmacy, Sichuan University, Chengdu 610064, China.
FAU - Chen, Meiwan
AU  - Chen M
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Institute of 
      Chinese Medical Sciences, University of Macau, Macau, China.
FAU - Gao, Huile
AU  - Gao H
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan 
      Research Center for Drug Precision Industrial Technology, West China School of 
      Pharmacy, Sichuan University, Chengdu 610064, China.
FAU - Wang, Ling
AU  - Wang L
AD  - Key Laboratory of Drug-Targeting and Drug Delivery System of the Education 
      Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan 
      Research Center for Drug Precision Industrial Technology, West China School of 
      Pharmacy, Sichuan University, Chengdu 610064, China.
LA  - eng
PT  - Journal Article
DEP - 20220404
PL  - Netherlands
TA  - Asian J Pharm Sci
JT  - Asian journal of pharmaceutical sciences
JID - 101535338
PMC - PMC9237596
OTO - NOTNLM
OT  - Comorbidity
OT  - Diabetes mellitus
OT  - Protein corona
OT  - Targeting capability
COIS- The authors report no conflicts of interest. The authors alone are responsible 
      for the content and writing of this article.
EDAT- 2022/07/06 06:00
MHDA- 2022/07/06 06:01
PMCR- 2022/04/04
CRDT- 2022/07/05 09:49
PHST- 2021/12/03 00:00 [received]
PHST- 2022/01/14 00:00 [revised]
PHST- 2022/03/04 00:00 [accepted]
PHST- 2022/07/05 09:49 [entrez]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/07/06 06:01 [medline]
PHST- 2022/04/04 00:00 [pmc-release]
AID - S1818-0876(22)00039-3 [pii]
AID - 10.1016/j.ajps.2022.03.002 [doi]
PST - ppublish
SO  - Asian J Pharm Sci. 2022 May;17(3):401-411. doi: 10.1016/j.ajps.2022.03.002. Epub 
      2022 Apr 4.